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Abstract To propose a novel procedure as a safe and effec-
tive treatment for cesarean scar pregnancy (CSP), a cohort
study was initiated in patients diagnosed with CSP and treated
with transvaginal hysterotomy fromDecember 2009 toMarch
2013, either as a primary or secondary therapy. All diagnoses
were confirmed by both sonography and pathology, either a
gestational sac or residual tissue after termination of pregnan-
cy or miscarriage in the cesarean section scar. Basic clinical
characteristics and perioperative data were collected and ana-
lyzed. A total of 40 patients were included. The mean age was
32.88±4.55 years. The mean size of gestational sacs of the
CSP mass at diagnosis was 33.78±13.14 mm.Mean serum β-
hCG level at diagnosis was 47379.73±45285.10 IU/L. Mean
operative time was 57.25±24.52 min. Mean postoperative
hemoglobin drop was 1.635±0.906 g/dL. Complications were
one case of bacteremia and two cases of hematoma. Mean
hospital stay after surgery was 4.95±2.62 days. Mean serum
β-hCG levels decreased by 88.5, 93.5, and 96.5 % at postop-
erative day 2, 4, and 6, respectively. All patients’ β-hCG
levels returned to normal range within 1 month after surgery.
Transvaginal hysterotomy with removal of ectopic pregnancy
tissue and repair of cesarean scar defect is a promising
approach to manage CSPs, with a short hospital stay, low
postoperative pain, blood loss, and cost.
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Introduction
As a rare form of ectopic pregnancy, cesarean scar pregnancy
(CSP) refers to the implantation of a pregnancy within the
myometrium at the site of a prior cesarean scar. If not detected
early and managed properly, CSP can result in life-threatening
complications, such as massive hemorrhage, uterine rupture,
disseminated intravascular coagulation, and even maternal
death [1]. Once diagnosed, therapy is strongly recommended
to avoid subsequent life-threatening complications. However,
no obvious most effective therapeutic strategy has been
established to date. Removal of the ectopic pregnancy tissue
is usually done. By following the concepts of minimally
invasive surgery, we designed and carried out the first case
of hysterotomy by transvaginal approach for the treatment of
CSP in 2009. A preliminary report of six cases was published
in 2011 with encouraging results [2]. Since 2009, we have
successfully completed 40 transvaginal CSP cases without
significant complications. Herein, we summarize our experi-
ence with this novel surgical approach for CSP and propose
the procedure as a safe, effective, and minimally invasive
treatment modality.
Patients and methods
All patients diagnosed with CSP and consented to have a
transvaginal surgery were enrolled in this study from
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December 2009 to March 2013. The study protocol was
approved by the institutional ethics committee of the univer-
sity, and all patients provided written informed consent before
enrollment.
Diagnosis and grouping
Cesarean scar pregnancy was diagnosed by ultrasonography
and β-human chorionic gonadotropin (β-hCG) level. The
diagnostic criteria for transvaginal ultrasound were as follows:
(1) an empty uterine cavity and cervical canal with a clearly
demonstrated endometrium and (2) a gestation sac, with or
without fetal cardiac activity, embedded in and surrounded by
the myometrium and the fibrous tissue of the cesarean section
scar in the anterior part of the uterine isthmus, that was
separated from the endometrial cavity or fallopian tube, with
a diminished or absent myometrial layer between the bladder
and the sac [3–5]. Patients with residual in the cesarean scar
tissue following spontaneaous miscarriage, termination of
pregnancy, or previous treatment of CSP were also included
as a subgroup. These were patients in whom the diagnosis was
made based on prolonged vaginal bleeding, elevated β-hCG
level, and a heterogeneous mass at the same site as the gesta-
tional sac described above. Previous treatments were consid-
ered unsatisfactory if the level of β-hCG failed to decrease
1 week after treatment, or massive vaginal bleeding
developed.
To confirm the diagnosis, morphologic and pathological
information were collected during and after surgery.
Treatment protocol
Preoperative preparation was the same as for other
transvaginal surgical procedures. All patients were placed in
a dorsal lithotomy position, and the bladder was emptied.
General anesthesia was applied. After a pair of vaginal retrac-
tors was placed into the vagina, the cervix was grasped and
manipulated with a toothed tenaculum. Adrenaline solution
(1.5 μg/mL; 10–20 mL) was injected submucosally for
hydrodissection and hemostasis before an incision was made
at the anterior cervicovaginal junction (Fig. 1a). The bladder
was dissected away until the anterior peritoneal reflection was
identified. The anterior retractor was inserted into the vaginal
incision to lift up the bladder. The CSP was identified as a
bluish bulge located in the anterior wall of the lower uterine
segment (Fig. 1b). A transverse incision was made on the
lower margin of the most prominent area of the bulge. Ectopic
pregnancy tissue was removed with sponge forceps or suction
through the incision on the uterus isthmus (Fig. 2). Thorough
curettage was done through the incision or cervical canal. The
edges of the incision were trimmed with scissors to remove all
of the scar tissue (Fig. 3). The myometrial (Fig. 4) and vaginal
Fig. 1 a Adrenaline solution was injected submucosally for
hydrodissection and hemostasis. b The bladder was dissected away and
the CSP (arrow) was identified as a bluish bulge located in the anterior
wall of the lower uterine segment
Fig. 2 Ectopic pregnancy tissue was removed with sponge forceps (a) or
suction (b) through the incision on the uterus isthmus
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(Fig. 5) incisions were closed with continuous locking sutures
using 2–0 absorbable sutures.
Postoperative assessment
Perioperative parameters included operating time, blood loss,
blood transfusion, conversion to laparotomy, complications
related to surgery, course of serum β-hCG titers, length of
hospital stay after surgery, and other adverse effects.
Follow-up assessments included remission of symptoms,
monitoring decrease of serum β-hCG titer, and resumption of
menstruation thereafter. Serum β-hCG level was monitored
every other day in the first week after the surgery and weekly
thereafter until the titers returned to normal levels.
Statistical analysis
Data were collected and evaluated for parametric analysis.
Mean±standard deviations (SD) are reported for continuous
data, whereas categorical data are presented as the absolute
count and percentage. ANOVA test was used to compare the
mean differences. P<0.05 was considered statistically signif-
icant. SPSS 13.0 software was used to perform statistical
analysis.
Results
A total of 40 consecutive patients with CSP who underwent
vaginal surgery were enrolled in the study. The baseline
clinical characteristics are presented in Table 1. Twenty-five
patients presented with vital pregnancy (Group A), 23 of
which had fetal heart activity at the moment of surgery. Eight
patients underwent medical treatment or embolization prior to
admission (Group B), including two cases of uterine artery
embolization (UAE) combined with local methotrexate
(MTX) injection, three cases of systemic MTX injection,
and three cases who received mifepristone treatment. All of
Fig. 3 The edges of the incision were trimmed with scissors to remove
all scar tissue
Fig. 4 The myometrial incision was closed with interrupted suture and
then continuous locking sutures
Fig. 5 The vaginal incision was closed with continuous locking sutures
Table 1 The baseline clinical characteristics of 40 patients a
Characteristic Mean±SD (range)a
Age (yr) 32.88±4.55 (24–43)
Interval from last cesarean section to surgical
treatment (month)
68.61±45.34 (9–188)
Gestational age (day) 58.59±16.48 (41–120)
Serum β-hCG level (IU/L) 47,379.73±45,285.10
(9.2–188,942)
Diameter of gestational sac (mass) on
ultrasound scan (mm)
33.78±13.14 (12–60)
a Data are given as mean±SD (range)
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these were considered unsatisfactory. The other seven patients
presented with residual products of conception in the cesarean
scar on ultrasound scan after spontaneous or elective abortion
(Group C). One patient had undergone three previous lower
segment transverse cesarean sections. Fourteen patients had
two previous cesarean sections. The remaining 25 patients had
one previous cesarean section. Twelve patients were asymp-
tomatic. Twenty-eight patients complained of various patterns
of vaginal bleeding, including one case of hemorrhagic shock.
Perioperative data on vaginal surgery is presented in
Table 2. None of the patients required conversion to
laparotomy. Blood transfusion was needed only for the
single patient who presented with hypovolemic shock at
admission. No excessive bleeding or injury to adjacent
organ was observed. Only one patient developed postop-
erative gram negative septicemia as demonstrated by
hemoculture. The patient completed a 7-day course of
antibiotic treatment and was subsequently discharged
without further signs of infection. Two patients devel-
oped a local hematoma that resolved spontaneously after
3 months with no further complications. The mean serum
β-hCG level decreased by 88.5, 93.5, and 96.5 % at
postoperative day 2, 4, and 6, respectively, comparing
to baseline. In all patients, trophoblast and scar tissue
within the uterine smooth muscle confirmed the patho-
logic diagnosis of CSP.
Gestational age, β-hCG level, and size of gestational sac
were not associated with operating time, hemoglobin decre-
ment, or length of hospital stay after surgery. The subgroup of
patients who underwent other treatment for CSP before vag-
inal surgery had significantly longer operating time than those
without previous treatment (73.1±28.2 vs. 52.2±23.2). He-
moglobin drop and length of hospital stay after surgery were
not significantly different among the subgroups (Table 3).
Finally, patients were categorized into two cohorts of 20 by
chronological order. Their age, gestational age, serum β-hCG
level, and size of gestational sac were comparable. Hospital
stay after surgery significantly decreased in the second group
(6.0±3.20 vs. 3.90±1.25). Though there was a trend for
shorter operating time (60.0±20.33 vs. 54.5±28.37) and he-
moglobin drop (18.25±8.69 vs. 14.45±9.23), this was not
significant.
Follow-up data were obtained from all patients between 2
and 36 months after surgery. Vaginal bleeding stopped around
1 week after transvaginal surgery. The serum β-hCG level in
all the cases resolved to normal range within 1 month after
surgery. All patients recovered without complications, no
subsequent treatment was needed, and there was no further
report of abnormal menstrual pattern.
Discussion
As CSP is an iatrogenic complication of cesarean section, the
incidence of CSP is likely to rise dramatically in the near
future due to the increase of cesarean section rates as well as
the increased utilization of diagnostic ultrasound. Since first
Table 2 Perioperative evaluation of the surgical procedure
Variable Mean±SD (range)a
Duration of surgery, (min) 57.25±24.52 (20–120)
Estimated blood loss during surgery, (mL) 47.88±35.71 (10–200)
Length of hospital stay after surgery, (day) 4.95±2.62 (2–17)
Hemoglobulin decreased after 24 h, (g/L) 16.35±9.06 (2–41)
a Data are given as Mean±SD (range)
Table 3 Comparison of subgroupsb
Sub-groupa
Group A (vital CSPs without
previous treatment)
Group B (CSPs with previous
conservative treatment)
Group C (CSPs with pregnant
tissue residues)
No. of cases 25 8 7
Age, (yr) 33.6±4.4 31.0±4.8 32.4±4.7
Serum β-hCG level (IU/L) 58,160.4±46,189.4d 40,481.4±36067.2 16,761.0±40,457.9b
Size of gestational sac (mass) on ultrasound
scan before surgery, (mm)
34.8±10.9 28.0±14.2 38.0±20.5
Duration of surgery, (min) 52.2±23.2c 73.1±28.2b 57.1±19.5
Hemoglobulin decrement within 24 h, (g/L) 17.0±10.1 13.3±7.4 17.7±6.7
Length of hospital stay after surgery, (day) 5.48±3.0 4.13±1.2 4.0±1.7
a Data are given as mean (SD). The mean difference is significant at the 0.05 level
b Significantly different from Group A
c Significantly different from Group B
d Significantly different from Group C
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being reported by Larsen and Solomon in 1978 [6], the
number of cases of CSP showed an exponential increase.
Between 1978 and 2001, only 18 cases of CSP were reported
in the English literature [3]. In a later review in 2007 [4], 161
cases of CSP from 58 citations were included. Jurkovic et al.
and Seow et al. have estimated the prevalence of CSP in their
local population attending the early pregnancy assessment
unit to be 1:1800 [7] and 1:2216 [8], respectively.
As a tertiary center in southern China, we have been
dealing with CSP for a long time. Our data through 2011
showed that CSPs constituted 2.2 % of ectopic gestations in
our hospital [2]. Before 2009, most of CSPs were managed by
UAE and MTX administration. Since the first transvaginal
hysterotomy in 2009, this treatment was explained to every
patient diagnosed with CSP as well as UAE. All patients
agreed to have vaginal surgery and provided informed con-
sent. It had been successfully performed in 40 cases of CSP.
In patients with prior cesarean section, transvaginal hyster-
otomy through the vesicouterine fold has met conceptual
hurdles mainly because of concerns for adhesions from prior
cesarean section scar and for injury of the bladder during
surgery. We have treated patients with β-hCG level as high
as 188,942 U/mL, gestational sac as large as 60 mm in
diameter, or gestational age as advanced as 10 weeks. The
mean operating time was no more than 1 h, and the mean
decrease in hemoglobin within 24 h was 1.635 g/dL, which is
tolerable for most patients. No major complications such as
massive bleeding or bladder injury were reported for any of
the cases. Mean hospital stay after surgery was less than
5 days, which could be further reduced to 3 or 4 days without
compromising safety. Serum β-hCG titers decreased by more
than 90 % before postoperative day 4 and resolved to normal
range within 1 month after surgery.
Based on our observations that prior conservative treatment
did not reduce operating time or hemoglobin loss, we do not
recommend prior medical treatment or UAE to improve safety
or efficacy of transvaginal surgery. There was both a difference
in operating time or hemoglobin drop between vital pregnancy
and those with residual tissue. Although in this series there was
no relationship between gestational age, β-hCG level and size
of gestational sac, and safety of surgery, it is probable that it is
more likely to encounter difficulties in more advanced gesta-
tion. Therefore, it would seem logical to recommend early
diagnosis by transvaginal ultrasound in pregnant women with
previous cesarean section, though our data cannot contribute to
the risk/benefit analysis of such strategy.
Although the exact pathogenetic mechanism of CSP is
unknown, a potential predisposing factor is a microtubular
tract between the cesarean section scar and the endometrial
canal. [3]. By removing the cesarean scar together with the
pregnancy tissue, we tried to avoid such persistent canal,
hence may reduce recurrence—though this cannot be proved
by the current study.
Before transvaginal surgery was described, MTX adminis-
tered either systemically or locally with UAE was the primary
management method in our hospital. Lian et al. [15] published
a series of 21 patients who received MTX (2005–2009). All
patients received systemic MTX (50 mg/m2) as initial therapy.
Only nine showed a rapid decrease of serum b-hCG within a
week, while MTX failed in the remaining 12. They had
additional UAE combined with local MTX. Although even-
tually all patients responded to MTX treatment with or with-
out UAE, it took 2 months to achieve serumβ-hCG resolution
and 6 months for the masses to disappear on ultrasound.
Moderate elevation of liver enzymes was documented in three
patients receiving systemic MTX, low grade fever (<38 °C) in
five, and low abdominal pain in three with UAE combined
with local MTX. In summary, MTX administration was asso-
ciated with slower recovery and more adverse effects.
Based on our experience, we suggest the following for
transvaginal hysterotomy approach to CSP management. Cer-
vical injection of diluted adrenaline solution is performed
before dissecting the vesicocervical gap to reduce bleeding.
This step may also help avoid injuring the bladder and urethra
and prevent the occurrence of vesicovaginal fistula formation.
We used suction and curettage for complete removal of the
products of conception as completely as possible. Continuous
yet locking sutures were used to repair the incision of the
anterior uterine wall under the guidance of a probe.
Prompt hysterectomy may be warranted only for dramatic
cases presenting with massive bleeding or shock. Most other
therapeutic options for CSPs have been adapted from proto-
cols used for the treatment of other locations of ectopic preg-
nancies. The medical therapies include systemic and local
administration of methotrexate (MTX), KCl, or the combina-
tion of these agents. The surgical treatments include dilatation
and curettage, selective UAE, operative hysteroscopy, lapa-
roscopy, and laparotomy. In cases of CSPs with decreasing
serial serum β-hCG levels, expectant management may be
offered. However, some reports showed that expectant man-
agement was associated with a high risk of uterine rupture
and, therefore, could not be recommended in most cases
[8–10]. Despite the effectiveness of MTX in decreasing the
serum β-hCG levels, systemic or local injection of MTX
requires close monitoring for a longer period of time. MTX
sometimes requires repeat injection that can be associated
with chemotherapy-induced side effects, slowly decreasing
serum β-hCG levels and longer hospitalization [4, 11]. More-
over, there is often incomplete reabsorption of the gestational
sac with ongoing irregular vaginal bleeding. Many of these
women need additional and sometimes more aggressive
methods to surgically remove the persistent gestational sac
and resolve the bleeding [11–13]. Uterine artery embolization
has been shown to carry risks of postoperative fever and
abdominal pain [14], as well as being associated with longer
duration of close monitoring and hospitalization [15].
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Surgery has the advantage of offering the possibility of im-
mediate remission. Hysteroscopy can be used to observe the
distribution of blood vessels at the implantation site and to
separate the gestational sac from the uterine wall directly. How-
ever, these procedures require good control of hysteroscopic
instruments, excellent orientation within the uterine cavity, and
clear visualization, which may not always be achievable [16]. In
addition, hysteroscopic resection carries a risk for bladder injury,
including delayed bladder perforation by thermal injury [17].
According to Fylstra’s review [3], termination of the pregnancy
with repair of the accompanying uterine scar dehiscence is
probably the best treatment for the cesarean scar pregnancy.
Laparoscopy is a minimally invasive option for resection of the
scar, with preservation of the woman’s reproductive capacity.
Although laparoscopic and laparotomy approaches have already
been successfully applied in CSPs [18, 19], a case report of CSP
showed that the lower edge of the uterine defect was not
accessible abdominally during emergency laparotomy. An ad-
ditional vaginal approach was needed to achieve hemostasis
[20]. This observation supports the feasibility of transvaginal
repair of the uterine defect after cesarean section. Furthermore,
compared to laparoscopy, transvaginal hysterotomy has the
advantage of avoiding trocar insertion, therefore reducing the
risks associated to this modality [21]. In addition, transvaginal
hysterotomy may decrease cost associated with the use of
equipment. As transvaginal hysterotomy requires only conven-
tional equipment and the general skills of vaginal surgery, it is
more convenient and more feasible to be conducted in most
hospitals at lower cost than other surgical approaches. Since our
first description, several other institutions employed this proto-
col successfully [22].
Conclusion
In summary, this transvaginal hysterotomy approach allows for
removal of ectopic pregnancy tissue and repair of uterine defect. It
is safe and effective, associated with a short hospital stay, low
postoperative pain, blood loss, and cost.
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